Skip to main content
. 2023 May 16;13:1096955. doi: 10.3389/fonc.2023.1096955

Figure 2.

Figure 2

The tumor response according to the mRECIST (1, CR; 2, PR; 3, SD; 4, PD) after 4 months of treatment and the progression pattern (Inline graphic, target; Inline graphic, new lesions; Inline graphic, non-target; Inline graphic, else) of the six PD patients. mRECIST, modified Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.